Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
AbbVie's new schizophrenia drug fails in trials, causing a 10% drop in the company's stock.
AbbVie's experimental schizophrenia drug, emraclidine, failed in two Phase 2 trials, not meeting the goal of reducing symptoms significantly compared to a placebo.
Despite the setback, which caused AbbVie's stock to drop over 10%, the company reports that the drug was well-tolerated.
Investment firm Cantor Fitzgerald remains optimistic about AbbVie's stock and pipeline.
14 Articles
El nuevo fármaco de esquizofrenia de AbbVie falla en los ensayos, causando una caída del 10% en las acciones de la compañía.